Incipiam Pharma ApS
CVR 44074214 · Private limited company (ApS) · Active · Medium risk
Incipiam Pharma ApS is a Private limited company (ApS), founded on , based in Valby. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 2 annual reports have been published. The latest annual report (30 Sep 2025) shows equity of DKK -1.9m and a net result of DKK -1.8m.
Bankruptcy risk for Incipiam Pharma ApS
1.0 × the average (1.41%) · higher risk than 77% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 44074214
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (3 years)
- Address
- c/o H. Lundbeck A/S, Ottiliavej 9
2500 Valby - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 40k
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 2 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -22.2% |
| Current ratio | 397% |
| Moves (last 2 years) | 2 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 9 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -1.2m | DKK -98k |
| Net profit | DKK -1.8m | DKK -128k |
| Equity | DKK -1.9m | DKK -101k |
| Total assets | DKK 8.8m | DKK 4.5m |
| Cash | DKK 8.2m | – |
| Short-term debt | DKK 2.2m | – |
| Avg. employees | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Oct 2024 – 30 Sep 2025 | 181 | ||
| 23 May 2023 – 31 Dec 2023 | 166 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| Owner (20%) | MTC 2008 HOLDING ApS | Current | |
| Owner (20%) | CTH Holding Invest ApS | Current | |
| Owner (20%) | Bondo Hansen Holding ApS | Current | |
| Owner (20%) | Gerhart-Hines Holding ApS | Current | |
| Owner (10%) | Receptor Holding ApS | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Founder | CTH Holding Invest ApS | Current |
Address history (2 moves)
| c/o H. Lundbeck A/S, Ottiliavej 9, 2500 Valby | |
| c/o BII, Ole Maaløes Vej 3, 2200 København N | |
| c/o Jusmedico Advokatanpartsselskab, Teknikerbyen 5, 2., 2830 Virum |
Other companies at the same address
- Embark Holdings ApS Active
- Embark Laboratories ApS Active
- H. LUNDBECK A/S Active
- LUNDBECK CHINA HOLDING A/S Opløst
- LUNDBECK COGNITIVE THERAPEUTICS A/S Fusioneret
- LUNDBECK EXPORT A/S Active
- LUNDBECK INS A/S Opløst
- LUNDBECK MIDDLE EAST A/S Fusioneret
- LUNDBECK PHARMA A/S Active
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Incipiam Pharma ApS
Has Incipiam Pharma ApS gone bankrupt?
No, Incipiam Pharma ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Incipiam Pharma ApS?
Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.
Who is the auditor of Incipiam Pharma ApS?
Incipiam Pharma ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Incipiam Pharma ApS founded?
Incipiam Pharma ApS was founded on 23 May 2023.
What is the equity of Incipiam Pharma ApS?
Equity was DKK -1.9m according to the annual report for the period ending 30 September 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.